冠状动脉内血栓形成在急性心肌梗塞的发病中占重要地位,约70～90%的急性透壁性心肌梗塞患者发病后在早期有冠状动脉内血栓堵塞。针对这一发病机制所采用的溶栓疗法在挽救濒死心肌、缩小梗塞范围、改善心脏功能方面已取得了良好效果。但常用的溶栓药物链激酶和尿激酶对循环血液的纤溶系统有全面激活作用,易引起“纤溶状态”(fibrilytic state),导致严重的出血并发症,故临床应用受到一定限制。具有血栓选择性作用的组织型纤维蛋白溶酶原激活 Coronary thrombosis in the incidence of acute myocardial infarction plays an important role, about 70 to 90% of patients with acute transmural myocardial infarction in the early onset of coronary thrombus occlusion. Thrombolytic therapy for this pathogenesis has achieved good results in rescuing dying myocardium, narrowing infarct size and improving cardiac function. However, the commonly used thrombolytic drugs streptokinase and urokinase have an overall activation effect on the fibrinolytic system of circulating blood and easily lead to fibrilytic state, leading to serious bleeding complications, so the clinical application is limited. Tissue type plasminogen activator with thrombus selectivity